2a:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/3ne0dxjrpj6b3.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/25k7ikgmcage7.js","/_next/static/immutable/chunks/32zk736rs0hqw.js","/_next/static/immutable/chunks/0lbgs964whs_0.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js","/_next/static/immutable/chunks/0hcnvyarhzl7i.js"],"default"] 2b:T5c33,

CATEGORY	DETAIL
Risk Factors	Immigration from or travel to endemic regions (Latin America, Sub-Saharan Africa, South and Southeast Asia, India). Close contact with a Taenia solium tapeworm carrier. Poor sanitation. Ingestion of food or water contaminated with T. solium eggs.
Etiology	Larval form (cysticercus) of Taenia solium (pork tapeworm) lodging in the central nervous system after fecal-oral ingestion of eggs.
Patient Presentation	New-onset seizures in a young adult from an endemic region. May also present with chronic headaches, focal neurological deficits, or signs of elevated intracranial pressure.
Classic Physical Exam	Often a normal neurological exam between seizure episodes. Papilledema if intracranial pressure is raised. Focal deficits (hemiparesis, visual field cuts) depending on cyst location. Subcutaneous nodules may be palpable on skin exam.
Key Diagnostic Results	CT head showing single or multiple ring-enhancing lesions, calcified parenchymal lesions, or cystic lesions with an eccentric hyperdense dot (the scolex). MRI brain showing cyst with a mural nodule (scolex). Positive serum enzyme-linked immunoelectrotransfer blot (EITB) antibody test.
Management	Antiparasitic therapy (albendazole) combined with corticosteroids (dexamethasone), plus antiepileptic drugs for seizure control. Steroids must be started before or simultaneously with antiparasitic agents.
Keywords	"Ring-enhancing lesion," "immigrant from Latin America," "new-onset seizures," "calcified brain lesion," "scolex," "cystic lesion with dot sign," "pork tapeworm."

1. Pathophysiology

Neurocysticercosis is caused by Taenia solium, the pork tapeworm, but the critical distinction tested on exams is the route of infection. A person develops intestinal taeniasis (the adult tapeworm in the gut) by eating undercooked pork containing encysted larvae. However, cysticercosis develops through an entirely different mechanism: fecal-oral transmission of T. solium eggs, not larvae. When a person ingests eggs shed in the feces of someone harboring an adult tapeworm, these eggs hatch in the small intestine, release oncospheres that penetrate the intestinal wall, enter the bloodstream, and disseminate throughout the body. The oncospheres have a strong predilection for the central nervous system, where they lodge in brain parenchyma, subarachnoid spaces, or ventricles and develop into fluid-filled larval cysts called cysticerci.

A viable cysticercus actively evades the host immune system by secreting immunomodulatory molecules. During this vesicular stage, the cyst wall is thin and translucent, the surrounding brain tissue shows minimal inflammation, and the patient is often asymptomatic. Symptoms arise when the larva begins to degenerate and lose its ability to suppress immunity. This triggers a vigorous host inflammatory response with perilesional edema, gliosis, and disruption of the surrounding neural tissue. It is this inflammation, not the cyst itself, that causes seizures, the most common clinical manifestation. The inflammation also explains why initiating antiparasitic therapy without concurrent corticosteroids can paradoxically worsen symptoms: killing the larvae accelerates antigen release, intensifies inflammation, and can provoke life-threatening cerebral edema.

In extraparenchymal disease, cysts lodging in the ventricles or subarachnoid space can obstruct cerebrospinal fluid (CSF) flow, leading to obstructive hydrocephalus. Subarachnoid cysts may grow in a lobulated, grape-like pattern called the racemose form, which provokes an arachnoiditis that further impairs CSF circulation and can cause progressive neurological decline.

2. Classification and Clinical Manifestation

Neurocysticercosis is classified both by anatomical location and by the biological stage of the cyst. Understanding the stage is essential because it determines imaging appearance and management decisions.

By Anatomical Location:

LOCATION	FREQUENCY	CLINICAL FEATURES
Parenchymal	Most common	Seizures (focal or generalized), headache, focal neurological deficits depending on cyst location
Ventricular	Less common	Acute obstructive hydrocephalus, positional headaches (Bruns syndrome if in the fourth ventricle), nausea, vomiting, altered consciousness
Subarachnoid (basal cisterns)	Less common	Chronic meningitis, cranial nerve palsies, communicating hydrocephalus, stroke from vasculitis
Subarachnoid (racemose)	Rare	Large multilobulated cysts in the Sylvian fissure or basal cisterns, mass effect, hydrocephalus
Spinal	Rare	Radiculopathy, myelopathy, cauda equina syndrome

By Cyst Stage (Parenchymal Disease):

STAGE	PATHOLOGY	IMAGING APPEARANCE	CLINICAL SIGNIFICANCE
Vesicular	Viable larva, thin cyst wall, minimal host response	Well-defined cystic lesion with visible scolex (eccentric dot), no surrounding edema, no enhancement	Usually asymptomatic; antiparasitic therapy is most effective here
Colloidal vesicular	Degenerating larva, intense perilesional inflammation	Ring-enhancing lesion with surrounding edema	Most symptomatic stage; seizures are most common here
Granular nodular	Cyst retracting, thickened wall, granuloma formation	Nodular enhancement, decreasing edema	Transitional; inflammation subsiding
Nodular calcified	Dead larva replaced by calcified granuloma	Punctate calcification without edema or enhancement	Often an incidental finding; seizures can still occur from perilesional gliosis; no antiparasitic therapy needed

3. Diagnostic Workup

TEST	ROLE	KEY FINDINGS
CT head (non-contrast)	Best initial test	Calcified parenchymal lesions, ring-enhancing lesions on contrast, cystic lesions with scolex
MRI brain with contrast	Most accurate test	Superior visualization of viable cysts, scolex (dot within the cyst), perilesional edema, ventricular and subarachnoid cysts
Serum EITB (enzyme-linked immunoelectrotransfer blot)	Confirmatory serologic test	Highly accurate for confirming T. solium antibodies; less sensitive with a single parenchymal lesion or calcified disease
Serum/CSF ELISA	Supportive	Detects anticysticercal antibodies; lower accuracy than EITB
CSF analysis	Supportive (extraparenchymal disease)	Lymphocytic pleocytosis, elevated protein, low glucose, eosinophils in CSF
Stool ova and parasites	Supportive (screens for intestinal carriage)	May reveal T. solium eggs or proglottids if the patient also harbors the adult worm
Fundoscopic exam	Required before treatment	Rules out intraocular cysticerci (antiparasitic therapy in the setting of ocular disease can cause irreversible vision loss)

Best Initial Test: CT Head. When a young adult from an endemic area presents with new-onset seizures, a non-contrast CT of the head is the first imaging study to order. CT is excellent for detecting calcified lesions (the hallmark of old, inactive disease) and can also reveal ring-enhancing lesions when contrast is administered. It is fast, widely available, and often provides enough information to raise strong clinical suspicion.

Most Accurate Test: MRI Brain. MRI is superior in nearly every other regard. It can identify the scolex within a viable cyst (appearing as a bright dot within a fluid-filled structure, sometimes called the "hole-with-dot" or "cyst-with-dot" sign), which is essentially pathognomonic. MRI is also far better at detecting cysts in the ventricles, subarachnoid space, and brainstem, locations where CT has limited resolution. For this reason, MRI is the preferred modality for staging disease and planning treatment.

Serologic Confirmation: EITB. The enzyme-linked immunoelectrotransfer blot is the most accurate blood test and is ordered to confirm the diagnosis when imaging is suggestive. However, sensitivity drops significantly in patients with only a single cyst or purely calcified disease, because the low antigen burden may not stimulate a detectable antibody response. A negative EITB does not rule out the diagnosis in these scenarios.

Before initiating antiparasitic therapy, a fundoscopic exam is mandatory. Intraocular cysticerci are a contraindication to antiparasitic treatment because the inflammatory response triggered by larval death within the eye can cause permanent blindness.

4. Management and Treatment

SCENARIO	TREATMENT	DETAILS
Parenchymal disease (viable cysts)	Albendazole + dexamethasone + antiepileptic drug	Albendazole 15 mg/kg/day divided BID (max 1200 mg/day) for 10 to 14 days. Dexamethasone 0.1 mg/kg/day started 1 day before antiparasitic and continued through the treatment course.
Heavy cyst burden (more than 2 viable cysts)	Albendazole + praziquantel + dexamethasone	Dual antiparasitic therapy: albendazole 15 mg/kg/day BID + praziquantel 50 mg/kg/day TID for 10 to 14 days. Higher-dose steroids may be needed.
Single enhancing lesion	Short-course albendazole + steroids + antiepileptic drug	Albendazole for 7 to 14 days. Many of these lesions resolve spontaneously, so some guidelines support observation with antiepileptics alone.
Calcified (inactive) lesions only	Antiepileptic drug alone	No antiparasitic therapy indicated. There is no living parasite to kill. Seizure management is the primary goal.
Ventricular cysts	Neuroendoscopic removal (preferred) or shunt placement	Antiparasitic therapy alone is risky because cyst swelling during treatment can acutely obstruct CSF flow. Surgical removal is first-line. Ventriculoperitoneal shunt if hydrocephalus persists.
Subarachnoid/racemose disease	Prolonged antiparasitic therapy + high-dose steroids + possible shunt	Albendazole for weeks to months; repeated courses often necessary. Shunting for hydrocephalus.
Intraocular or spinal cysts	Surgical excision	Antiparasitic therapy is contraindicated for ocular cysts. Surgical removal is mandatory.
Seizure management	Antiepileptic drug	Levetiracetam or carbamazepine are commonly used. Duration depends on recurrence risk and whether calcified lesions persist.

Acute Stabilization. The immediate priority is seizure control. Start an antiepileptic drug (levetiracetam is commonly chosen for its favorable side-effect profile). If the patient presents with signs of elevated intracranial pressure or hydrocephalus, address this with corticosteroids and neurosurgical consultation before any antiparasitic therapy.

Corticosteroids Before Antiparasitics. This is a high-yield management principle. Dexamethasone (or prednisolone as an alternative) must be initiated before or at the same time as antiparasitic therapy to blunt the inflammatory surge caused by cyst destruction. Failing to do this can precipitate worsening cerebral edema, status epilepticus, or herniation.

Antiparasitic Therapy. Albendazole is the preferred agent due to better CNS penetration and fewer drug interactions compared to praziquantel. For patients with more than two viable parenchymal cysts, combination therapy with both albendazole and praziquantel has been shown to improve cyst resolution rates. Praziquantel levels are reduced by concurrent dexamethasone (which induces hepatic metabolism of praziquantel), while albendazole levels are actually increased by dexamethasone, making albendazole the more reliable agent when steroids are co-administered.

Long-Term Management. Patients with calcified lesions remain at risk for recurrent seizures due to perilesional gliosis. Long-term antiepileptic therapy is often necessary, and the decision to discontinue should be individualized based on seizure recurrence, EEG findings, and persistence of calcifications on follow-up imaging.

Contraindications to Antiparasitic Therapy: Antiparasitic drugs should not be given in the following situations:

Intraocular cysticerci (risk of irreversible vision loss)
Purely calcified/inactive disease (no viable parasite to treat)
Diffuse cerebral edema or cysticercal encephalitis from extremely heavy cyst burden (treat with steroids first, defer antiparasitic)
Unstable patients with uncontrolled intracranial hypertension (stabilize before treating the infection)

5. Differential Diagnosis and Distractors

DIFFERENTIAL	WHY IT IS SIMILAR	KEY DISCRIMINATOR
Cerebral toxoplasmosis	Multiple ring-enhancing brain lesions, seen in immigrants.	Toxoplasmosis occurs in severely immunocompromised patients (CD4 count below 100). Lesions favor the basal ganglia. The patient will have known HIV/AIDS. Neurocysticercosis occurs in immunocompetent patients.
Brain abscess (bacterial)	Ring-enhancing lesion with surrounding edema, seizures possible.	Bacterial abscess shows restricted diffusion on DWI-MRI (bright on DWI, dark on ADC). Patient typically has fever, elevated WBC, and a source of infection (sinusitis, endocarditis, dental abscess). Cysticercosis shows the scolex within the cyst and lacks restricted diffusion.
Primary or metastatic brain tumor	Ring-enhancing or cystic lesion, seizures, focal deficits.	Tumors tend to show progressive neurological decline, irregular thick-walled enhancement, and mass effect without a visible scolex. No calcification pattern typical of cysticercosis.
Tuberculoma	Ring-enhancing granuloma, common in patients from endemic regions with overlap in geography.	Look for systemic TB features: pulmonary findings on chest X-ray, positive tuberculin skin test, constitutional symptoms (weight loss, night sweats, chronic cough). CSF in TB meningitis shows very low glucose and very high protein.
Cerebral hydatid disease (Echinococcus)	Large cystic brain lesion in a patient from an endemic pastoral region.	Hydatid cysts are typically solitary, large, and do not show the scolex "dot sign." History of exposure to dogs and livestock. Rupture of a hydatid cyst can cause anaphylaxis. Cysticercosis cysts are usually smaller and multiple.
Cerebral malaria	Seizures, altered mental status in a traveler from an endemic area.	Cerebral malaria presents acutely with high fever, severe hemolytic anemia, thrombocytopenia, and diffuse cerebral edema rather than discrete cystic or calcified lesions. Peripheral smear shows parasitized red blood cells.

6. Traps and High-Yield Pearls

The single most common trap on this topic is confusing the route of acquisition for cysticercosis versus intestinal taeniasis. Students frequently associate T. solium with eating undercooked pork, which is only true for developing the adult tapeworm in the intestine. Cysticercosis, including neurocysticercosis, results from ingesting eggs via the fecal-oral route, meaning a strict vegetarian living with a tapeworm carrier can develop the disease. Vignettes will test whether you understand this distinction.

The second major trap involves management sequencing. A question may present a patient with viable brain cysts and seizures, then ask for the "next best step." Students who jump directly to antiparasitic therapy will get the question wrong. The correct answer is to start corticosteroids and antiepileptic drugs first (or concurrently with antiparasitics), because killing the cysts without anti-inflammatory coverage can cause fatal cerebral edema.

A third tested concept is knowing when not to give antiparasitics. If the imaging shows only calcified lesions with no viable cysts, the parasite is already dead. Treating with albendazole adds toxicity without benefit. The management in this scenario is antiepileptic therapy alone.

Finally, watch for the vignette that mentions a "cystic lesion with an eccentric bright dot" on MRI. This is the scolex, the larval head within the cyst, and it is pathognomonic for neurocysticercosis. No other ring-enhancing lesion will present with this finding, and recognizing it allows you to commit to the diagnosis with confidence. The core competency being tested across all question variants is your ability to integrate epidemiologic risk, imaging pattern recognition, and the principle that inflammation (not the parasite itself) drives the clinical syndrome and dictates treatment sequencing.

1b:["$","$L2a",null,{"article":{"id":"63e5bc8a-49a6-4df6-a612-7c838f06cd9d","title":"Neurosistiserkosis","content":"$2b","category":"Neurologi","created_at":"2026-09-04T14:39:14.80238+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]